Tecan Group (TECN) CMD 2024 summary

Strategic and market positioning

• Focus on scaling healthcare innovation globally, leveraging strong positions in life sciences, OEM partnering, and global megatrends such as aging populations and digital transformation.

• Addressing high-growth segments in genomics, proteomics, cellomics, and medtech, with a total addressable market of CHF 24-25 billion and robust mid-single-digit CAGR.

• Emphasis on modularity, digitalization, and recurring revenue to drive above-market growth and profitability, with expansion of digital ecosystem and automation to address labor shortages and workflow complexity.

• Expansion into high-potential regions, including direct presence in South Korea, enhanced localization in China, and commercial expansion in Americas, Europe, and Asia.

• Sustainability integrated into strategy, with Science Based Targets initiative, renewable energy use, and comprehensive reporting.

Financial performance and guidance

• 2024 guidance revised to -12% to -14% sales decline in local currencies and EBITDA margin of 16%-18% due to OEM partner demand deferrals, especially in China.

• Mid-term outlook reaffirmed: organic sales growth in mid- to high-single digits, with 30-50 bps annual EBITDA margin expansion once 20% margin is regained.

• Cost control measures implemented, including workforce reduction, facility consolidation, supply chain vertical integration, and footprint adaptation, lowering breakeven to CHF 1 billion in revenues.

• Strong cash flow conversion (80%+ EBITDA to operating cash), supporting disciplined M&A and innovation investments, with 72% of capital allocated to acquisitions since 2019.

• CapEx remains low, with flexibility for acquisitions, dividends, and innovation reinvestment.

Business developments and innovation

• Launch of Veya, a digitally empowered, modular automation platform targeting low-to-medium throughput labs, complementing the high-end Fluent system and democratizing lab automation.

• Continued investment in digital solutions, including LabNavigator, MAPlinx, modular software, fleet management, and remote diagnostics to enhance customer experience and operational efficiency.

• Strategic partnerships and innovation in liquid biopsy, 3D cell models, proteomics, and mass spec sample prep, with flagship products like Phase Separator and Resolvex i300.

• Partnering business strengthened by Paramit acquisition, expanding into medtech and contract manufacturing, with a global R&D and manufacturing network and FDA Class III device capabilities.

• Focused account management, cross-selling, and expanded service offerings across Synergence, Cavro, and Paramit brands to drive long-term, multi-year OEM relationships.